Vanguard Group Inc Exelixis, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 27,469,094 shares of EXEL stock, worth $1.04 Billion. This represents 0.02% of its overall portfolio holdings.
Number of Shares
27,469,094
Previous 28,671,987
4.2%
Holding current value
$1.04 Billion
Previous $1.06 Billion
14.38%
% of portfolio
0.02%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding EXEL
# of Institutions
688Shares Held
260MCall Options Held
1.41MPut Options Held
1.55M-
Black Rock Inc. New York, NY33.5MShares$1.26 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA16MShares$604 Million3.18% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.8MShares$596 Million0.99% of portfolio
-
State Street Corp Boston, MA11.4MShares$429 Million0.02% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA8.78MShares$331 Million1.43% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.1B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...